Business ❯ Pharmaceuticals

Biopharmaceuticals

Drug Development Manufacturing Research and Development Product Development Oncology Acquisitions Biosimilars Partnerships Leadership Innovative Medicines Metabolic Diseases Patent Law Merck KGaA Rare Diseases Anticoagulation Therapy Neurology Active Pharmaceutical Ingredients Lifecore Biomedical Regulatory Affairs Contract Manufacturing Therapeutics Clinical Trials Radiopharmaceuticals Medical Devices Employee Compensation Cell-based Therapies

Johnson & Johnson Hits Record After Analyst Upgrade and Strong Drug Prescriptions

Guggenheim cited better-than-expected Tremfya, Caplyta and Erleada prescription trends and investors are focused on the July 15 earnings call to see if sales sustain the rally.

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

Pfizer Settles With Three Generics to Keep Vyndamax Exclusive Until 2031

JW Pharmaceutical Licenses Korean Rights to Gan & Lee’s GLP-1 Drug in Deal Worth Up to $81 Million

GSK to Acquire 35Pharma for $950 Million to Add Pulmonary Hypertension Candidate HS235

AbbVie to Invest $380 Million in Two North Chicago API Plants

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views

Telix Faces Securities Class Action Over Prostate Cancer Disclosures and Supply Chain Claims

Telix Hit With Securities Class Action Over Prostate-Drug Claims and Supply Chain Assurances